Seiwert T - Search Results

1

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Seiwert T, Sarantopoulos J, Kallender H, McCallum S, Keer HN, Blumenschein G Jr. Seiwert T, et al. Invest New Drugs. 2013 Apr;31(2):417-24. doi: 10.1007/s10637-012-9861-3. Epub 2012 Aug 24. Invest New Drugs. 2013. PMID: 22918720 Free PMC article. Clinical Trial.

2

Clinical Uncertainties of Circulating Tumor DNA in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma in the Absence of National Comprehensive Cancer Network Guidelines.

Xie DX, Kut C, Quon H, Seiwert TY, D'Souza G, Fakhry C. Xie DX, et al. J Clin Oncol. 2023 May 10;41(14):2483-2487. doi: 10.1200/JCO.22.00264. Epub 2022 Dec 9. J Clin Oncol. 2023. PMID: 36493337 Free PMC article. No abstract available.

3

State-of-the-art management of locally advanced head and neck cancer.

Seiwert TY, Cohen EE. Seiwert TY, et al. Br J Cancer. 2005 Apr 25;92(8):1341-8. doi: 10.1038/sj.bjc.6602510. Br J Cancer. 2005. PMID: 15846296 Free PMC article. Review.

4

A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.

Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE. Seiwert TY, et al. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):515-22. doi: 10.1158/1078-0432.CCR-06-1058. Clin Cancer Res. 2007. PMID: 17255273 Clinical Trial.

5

The chemoradiation paradigm in head and neck cancer.

Seiwert TY, Salama JK, Vokes EE. Seiwert TY, et al. Nat Clin Pract Oncol. 2007 Mar;4(3):156-71. doi: 10.1038/ncponc0750. Nat Clin Pract Oncol. 2007. PMID: 17327856 Review.

6

A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.

Seiwert TY, Cohen EE, Haraf DJ, Stenson K, Blair EA, Mauer A, Dekker A, Vokes EE. Seiwert TY, et al. Cancer Invest. 2007 Sep;25(6):435-44. doi: 10.1080/07357900701357993. Cancer Invest. 2007. PMID: 17882655 Clinical Trial.

7

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.

Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX, Vokes EE. Seiwert TY, et al. J Clin Oncol. 2008 Apr 1;26(10):1732-41. doi: 10.1200/JCO.2007.13.1706. J Clin Oncol. 2008. PMID: 18375903 Clinical Trial.

8

Targeting angiogenesis in head and neck cancer.

Seiwert TY, Cohen EE. Seiwert TY, et al. Semin Oncol. 2008 Jun;35(3):274-85. doi: 10.1053/j.seminoncol.2008.03.005. Semin Oncol. 2008. PMID: 18544442 Review.

9

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, Pierce C, Dancey JE, Stenson K, Blair E, Dekker A, Vokes EE. Cohen EE, et al. Lancet Oncol. 2009 Mar;10(3):247-57. doi: 10.1016/S1470-2045(09)70002-6. Epub 2009 Feb 7. Lancet Oncol. 2009. PMID: 19201650 Free PMC article. Clinical Trial.

10

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. Seiwert TY, et al. Cancer Res. 2009 Apr 1;69(7):3021-31. doi: 10.1158/0008-5472.CAN-08-2881. Epub 2009 Mar 24. Cancer Res. 2009. PMID: 19318576 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

144 results

Search Page

Filters